Tumor analysis. Determine course of care.
Identify potential candidates for additional therapy.
SmartKidney Dx™, in the final stage of development, is a biomarker- and algorithm-based direct tissue measurement that potentially predicts the presence or the risk of metastases.
Personalized Healthcare
- SmartKidney Dx is designed with the intention of identifying patients who are candidates for additional therapy, due to undiagnosed micro-metastases by the current standard of care.
- This test aims to help accelerate the course of treatment by reducing risk of disease progression through early intervention.
- Partnered and collaborated on the development of SmartKidney Dx with Mayo Clinic and licensed with Mayo Ventures.